Ornidazole is a second-generation 5-nitroimidazole derivative antimicrobial agent, structurally related to metronidazole and tinidazole. It is a prodrug that is selectively activated by anaerobic and protozoal pathogens, leading to cytotoxic effects. The 0.5% w/v concentration is primarily formulated for topical application in dermatological and gynecological infections, offering localized action with minimal systemic absorption and side effects. It is a cornerstone therapy for bacterial vaginosis and amoebic infections in the Indian context.
Adult: **Topical (0.5% w/v Gel/Cream/Lotion):** Apply a thin layer to the affected area twice daily. **Vaginal Gel:** One 5g applicatorful (approx. 25 mg ornidazole) intravaginally, usually at bedtime for 5 days. **Oral/Systemic:** For amoebiasis: 1.5 g once daily for 3-5 days. For giardiasis/trichomoniasis: 1.5 g as a single dose or 500 mg twice daily for 5 days. For anaerobic infections: 500 mg twice daily for 5-10 days.
Note: **Topical:** Clean and dry the affected area before application. Apply a thin film and rub gently. Wash hands after application. Avoid contact with eyes, mouth, and mucous membranes unless formulated for such use (e.g., vaginal gel). **Oral:** To be taken with or after food to minimize gastrointestinal upset. Complete the full prescribed course.
Ornidazole is a prodrug. Its nitro group is reduced intracellularly by low-redox potential electron transport proteins (ferredoxin or flavodoxin) found in anaerobic bacteria and protozoa. This reduction forms short-lived, cytotoxic nitro radical anions. These radicals cause strand breaks in microbial DNA, inhibit nucleic acid synthesis, and destabilize the DNA helix, leading to cell death. Aerobic cells lack these reducing pathways, conferring selective toxicity.
Pregnancy: **Category B (US FDA).** Animal studies show no risk, but adequate human studies are lacking. **Systemic use is contraindicated in the first trimester.** Use in second/third trimester only if potential benefit justifies potential risk. **Topical use (vaginal gel, skin cream)** is generally considered to have minimal systemic absorption and lower risk, but should be used under strict medical supervision.
Driving: May cause dizziness, drowsiness, visual disturbances, or confusion. Patients should be cautioned about driving or operating machinery if they experience these effects, particularly with systemic therapy.
| Alcohol (Ethanol) | Risk of disulfiram-like reaction (flushing, palpitations, nausea). Although less pronounced than with metronidazole, concurrent use should be avoided during and for at least 72 hours after systemic therapy. | Major |
| Warfarin and other Coumarin Anticoagulants | Ornidazole may potentiate anticoagulant effect by inhibiting metabolism, increasing INR and risk of bleeding. Monitor INR closely. | Major |
| Lithium | May increase lithium serum levels and risk of toxicity. Monitor lithium levels. | Moderate |
| Cyclosporine, Tacrolimus | Ornidazole may increase levels of these calcineurin inhibitors via CYP3A4 inhibition, increasing risk of nephrotoxicity and neurotoxicity. Monitor drug levels. | Moderate |
| Phenobarbital, Phenytoin | These CYP450 inducers may increase the metabolism of ornidazole, reducing its plasma concentration and efficacy. | Moderate |
| Fluorouracil (5-FU) | Nitroimidazoles may reduce clearance of 5-FU, potentially increasing toxicity. | Moderate |